CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
打破壁垒：更智能的 CAR 工程化 NK 细胞对抗实体瘤的潜力
英文原题：Breaking down barriers: The potential of smarter CAR-engineered NK cells against solid tumors.
查看英文原题
Breaking down barriers: The potential of smarter CAR-engineered NK cells against solid tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
自然杀伤（NK）细胞被认为是先天免疫系统中对抗外来入侵者的首要战士，因此往往能迅速锁定感染病毒的细胞和肿瘤/癌细胞，通过吞噬作用将其杀死。目前，基因工程化嵌合抗原受体（CAR）的应用确保了NK细胞具有乐观的反应，并且不会让受影响的细胞不受控制地逃避或逃脱。因此，与CAR-T 疗法相比，CAR-NK细胞的特异性和独特性使其成为更好的免疫治疗选择，能够以比CAR-T 免疫疗法更完整的方式减轻大量肿瘤细胞在健康细胞群附近转运的负荷。我们的综述主要关注临床前、临床及临床研究试验的最新进展，以及实现针对实体瘤增强且高效治愈的进一步策略。
展开英文摘要原文
Natural killer (NK) cells are considered to be the foremost fighters of our innate immune system against foreign invaders and thus tend to promptly latch onto the virus-infected and tumor/cancerous cells, killing them through phagocytosis. At present, the application of genetically engineered Chimeric antigen receptor (CAR) receptors ensures a guaranteed optimistic response with NK cells and would not allow the affected cells to dodge or escape unchecked.
Hence the specificity and uniqueness of CAR-NK cells over CAR-T therapy make them a better immunotherapeutic choice to reduce the load of trafficking of numerous tumor cells near the healthy cell populations in a more intact way than offered by CAR-T immunotherapy.
Our review mainly focuses on the preclinical, clinical, and recent advances in clinical research trials and further strategies to achieve an augmented and efficient cure against solid tumors.
论文信息
- 作者
- Khawar MB、Gao G、Rafiq M、Shehzadi A、Afzal A、Abbasi MH、Sheikh N、Afzal N
- 单位
- Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Journal of cellular biochemistry2023 Aug
- 原文标识
- PubMed 37566723 · DOI 10.1002/jcb.30460